FAS and fatty liver disease: However, SR treatment attenuated HFD-induced hepatic steatosis by suppressing TG contents and the expression of fatty acid transport- and lipogenesis-related genes including Fabp1, Fabp4, Slc27a5, Pparg, Mlxipl, Srebf1, Srebf2, Fas, Dgat1, and Dgat2 (Figure 6).